课题基金 / 基金详情

CALCIUM MODULATION OF COLON CANCER INTERMEDIATE MARKERS

CALCIUM MODULATION OF COLON CANCER INTERMEDIATE MARKERS
结肠癌中间标志物的钙调节
批准号:
3423258
负责人:
PATRICK M. LYNCH
金额:
$3.46万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-09-10 至 1990-08-31

项目摘要

项目成果

PATRICK M. LYNCH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A high risk for colon cancer may correlate positively with the, proliferative activity or enzymatic activity in colon mucosa as measured by several assays: tritiated thymidine autoradiography, bromodeoxyuridine immunoperoiddase, and ornithine decarboxylue activity. The proliferative activity of colonic crypt cells has been reported to be suppressed by the administration of oral calcium. Many issues remain to be explored in determining the precise role of calcium in the modulation of colonic cell proliferation and the validity of intermediate markers of proliferation in monitoring this offect. This study proposes to evaluate four high-risk groups for colorectal cancer: a) patients with previous sporadic-type colon cancer, b) patients with a previous colon cancer who are members of a family with hereditary non-polyposis colon cancer (HNPCC); c) asymptomatic individuals at 50% risk of developing colon cancer because of a family history of HNPCC; d) patients with familial polyposis coli (FPC). Following stratification to one of the risk-groups, subjects are randomized to receive either oral calcium (2 g/day) or placebo for 12 weeks, followed by a cross over to the altenate regimen for 12 weeks. Proliferative activity (tritiated thymidine, bromodeoxyuridine labeuing and omithine decarboxylase activity) are measured on rectal biopsy at study entry, and after each of the two study periods (ie placebo or CaCO3). Proliferative and enzymatic activity profiles will be developed for each high risk group and the degree of modulation by oral calcium administration determined. It is anticipated that subject enrolled will be followed prospectively in order to evaluate long-term trends of labelling activity, calcium modulation, and clinical correlation. Issues related to long-term cancer control objectives will be considered. These will include evaluation of subject recruitment, study compliance and drop-out, as well as overall patient acceptance of study requirements.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GE
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
海外基金